Edgar Filing: Adaptimmune Therapeutics PLC - Form 4

Adaptimmune Therapeutics PLC Form 4 May 18, 2016 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Sigal Charles Elliott Issuer Symbol Adaptimmune Therapeutics PLC (Check all applicable) [ADAP] (Last) (First) (Middle) 3. Date of Earliest Transaction X_ Director 10% Owner Other (specify Officer (give title (Month/Day/Year) below) below) **32 BREARLY ROAD** 05/16/2016 (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting PRINCETON, NJ 08540 Person (Zip) (City) (State) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 4. Securities Acquired 7. Nature of 3. 5. Amount of 6. Security (Month/Day/Year) Execution Date, if Transaction(A) or Disposed of (D) Securities Ownership Indirect (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Beneficial any (Month/Day/Year) (Instr. 8) Owned Direct (D) Ownership Following or Indirect (Instr. 4) Reported (I) (A) Transaction(s) (Instr. 4) or (Instr. 3 and 4) Code V Amount (D) Price Ordinary Shares with Shares held a nominal by Sigal 15.000 \$ 1.5 value of 05/16/2016 Р 269,100 (4) I Family Α (2) (3) GBP0.001 Investments, LLC per share (1) Ordinary 05/17/2016 Ρ 15.000 A \$ 284,100 (6) I Shares held Shares with (2) 1.53 by Sigal (5) a nominal Family Investments, value of GBP0.001 LLC

per share (1)							
Ordinary Shares with a nominal value of 05/18/2016 GBP0.001 per share (1)	Р	15,000 (2)	A	\$ 1.55 (7)	299,100 <u>(8)</u>	Ι	Shares held by Sigal Family Investments, LLC
Ordinary Shares with a nominal value of GBP0.001 per share					52,938 <u>(9)</u>	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	Date	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owno Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Sigal Charles Elliott							
32 BREARLY ROAD	Х						
PRINCETON, NJ 08540							

Signatures

**Signature of Reporting Person

/s/ Charles Elliott Sigal

05/18/2016

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Dr. Sigal is a manager of Sigal Family Investments, LLC. Dr. Sigal may be deemed to have voting and investment power over the shares(1) held by Sigal Family Investments, LLC. Dr. Sigal disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

- (2) The 15,000 Ordinary Shares are represented by 2,500 American Depositary Shares ("ADSs") which are held by Sigal Family Investments, LLC. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc.
- (3) The price of \$1.50 per Ordinary Share was derived from the purchase price paid on May 16, 2016, of \$8.98 per ADS, divided by six.

(4) The 269,100 Ordinary Shares comprise (i) 254,100 Ordinary Shares, and (ii) 15,000 Ordinary Shares represented by 2,500 ADSs.

- (5) The price of \$1.53 per Ordinary Share was derived from the purchase price paid on May 17, 2016, of \$9.18 per ADS, divided by six.
- (6) The 284,100 Ordinary Shares comprise (i) 254,100 Ordinary Shares, and (ii) 30,000 Ordinary Shares represented by 5,000 ADSs.
- (7) The price of \$1.55 per Ordinary Share was derived from the purchase price paid on May 18, 2016, of \$9.30 per ADS, divided by six.
- (8) The 299,100 Ordinary Shares comprise (i) 254,100 Ordinary Shares, and (ii) 45,000 Ordinary Shares represented by 7,500 ADSs.
- (9) The 52,938 Ordinary Shares are represented by 8,823 ADSs.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.